HomeCompareADVM vs GBDC

ADVM vs GBDC: Dividend Comparison 2026

ADVM yields 45.87% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBDC wins by $20.53M in total portfolio value· pulled ahead in Year 6
10 years
ADVM
ADVM
● Live price
45.87%
Share price
$4.36
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$317.6K
Annual income
$60,065.20
Full ADVM calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — ADVM vs GBDC

📍 GBDC pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodADVMGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ADVM + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ADVM pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ADVM
Annual income on $10K today (after 15% tax)
$3,899.08/yr
After 10yr DRIP, annual income (after tax)
$51,055.42/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, GBDC beats the other by $13,932,068.34/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ADVM + GBDC for your $10,000?

ADVM: 50%GBDC: 50%
100% GBDC50/50100% ADVM
Portfolio after 10yr
$10.58M
Annual income
$8,255,399.52/yr
Blended yield
78.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ADVM right now

ADVM
Analyst Ratings
10
Buy
6
Hold
Consensus: Buy
Price Target
$4.83
+10.8% upside vs current
Range: $4.00 — $5.50
Altman Z
-32.7
Piotroski
1/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ADVM buys
0
GBDC buys
0
No recent congressional trades found for ADVM or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricADVMGBDC
Forward yield45.87%11.86%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$317.6K$20.85M
Annual income after 10y$60,065.20$16,450,733.83
Total dividends collected$248.2K$20.43M
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy
Analyst price target$4.83$14.00

Year-by-year: ADVM vs GBDC ($10,000, DRIP)

YearADVM PortfolioADVM Income/yrGBDC PortfolioGBDC Income/yrGap
1$15,287$4,587.16$12,492$1,791.70+$2.8KADVM
2$22,911$6,553.70$16,527$3,160.58+$6.4KADVM
3$33,694$9,179.50$23,588$5,904.90+$10.1KADVM
4$48,670$12,616.75$37,141$11,901.65+$11.5KADVM
5$69,108$17,032.01$66,205$26,463.38+$2.9KADVM
6← crossover$96,549$22,602.46$137,452$66,612.65$40.9KGBDC
7$132,818$29,511.17$342,372$195,298.53$209.6KGBDC
8$180,057$37,941.48$1,053,292$686,954.33$873.2KGBDC
9$240,732$48,070.97$4,111,439$2,984,416.95$3.87MGBDC
10$317,648$60,065.20$20,849,974$16,450,733.83$20.53MGBDC

ADVM vs GBDC: Complete Analysis 2026

ADVMStock

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Full ADVM Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this ADVM vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ADVM vs SCHDADVM vs JEPIADVM vs OADVM vs KOADVM vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.